2026-07-13 FDA Warning Letter: BioMylz Pvt. Ltd. Cited for CGMP/Finished Pharmaceuticals/Adulterated/Misbranded
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated/Misbranded
TL;DR
The short version: The FDA issued a warning letter to BioMylz Pvt. Ltd. (FEI 3013697420) on July 13, 2026, following an inspection February 4-9, 2026, citing significant CGMP violations for finished pharmaceuticals at its Bengaluru facility. Violations included failure by the quality control unit to retain complete manufacturing and laboratory records (including original batch records and test data found in a garbage bag), inadequate laboratory logbook controls with pencil-to-ink alterations, repeated data integrity breaches by facility management including destruction and falsification of records, and incomplete drug listing information for Soraresal Cream (NDC 73526-002) and Equate Medicated Vaporizing Steam Liquid (NDC 73559-011) in FDA's eDRLS system. The firm's February 27, 2026 response was deemed inadequate for failing to provide supporting documentation or evidence of corrective actions.
Argus analysis
# FDA Warning Letter Analysis: BioMylz Pvt. Ltd.
**Company and Violations**
BioMylz Pvt. Ltd., a pharmaceutical manufacturer in Bangalore, India (FEI 3013697420), received a warning letter from FDA's Center for Drug Evaluation and Research on July 13, 2026, following a February 2026 inspection. FDA found significant Current Good Manufacturing Practice (CGMP) violations in the production of over-the-counter drugs, including a topical psoriasis cream (Soraresal Cream, NDC 73526-002) and a medicated vaporizing liquid (Equate Medicated Vaporizing Steam Liquid, NDC 73559-011) intended for U.S. distribution. The agency determined that manufacturing methods, facilities, and controls do not conform to CGMP requirements, rendering products adulterated and misbranded.
**Regulatory Citations and Implications**
The inspection identified violations under 21 CFR parts 210 and 211, which establish mandatory CGMP standards for pharmaceutical manufacturing. Specific citations include 21 CFR 211.22, addressing quality control unit responsibilities for ensuring product compliance with identity, strength, quality, and purity specifications. FDA also cited deficiencies in drug listing submissions under section 510(j) of the FD&C Act. These regulations require manufacturers to maintain contemporaneous, accurate records; control laboratory logbooks; and retain original analytical data supporting batch release decisions. BioMylz's documented failures—including discovered records in a garbage bag, handwritten entries altered from pencil to ink, unnumbered logbook pages, and absent original laboratory data—constitute systemic data integrity breaches rather than isolated lapses.
**Timeline and Industry Observations**
BioMylz must submit a comprehensive response addressing the warning letter's detailed requirements. Compliance officers in pharmaceutical manufacturing should monitor whether the company engages independent third-party consultants for remediation, implements a retrospective data evaluation, and establishes enhanced oversight mechanisms. Industry peers should note FDA's escalating scrutiny of data integrity practices and the agency's expectation of substantive corrective action plans supported by documentation of systemic improvements before operations resume.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER BioMylz Pvt. Ltd. MARCS-CMS 729483 — July 13, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS Reference #: 320-26-103 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Vasanth Samaga Recipient Title Founder-Director BioMylz Pvt. Ltd. # cj-1, Santra Magan Place Apartment off Banneraghatta Road Doddakammanahalli, near Maruthi Dental College Bangalore 560076 India Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-103 July 13, 2026 Dear Mr. Samaga: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, BioMylz Pvt. Ltd., FEI 3013697420, at #21 - D #21 - D Building No 1, Bengaluru, Karnataka, India, from February 4 to 9, 2026. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). In addition, violations were identified and documented during a review of your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS). Based on our review, you failed to provide complete drug listing information for your Soraresal Cream, NDC 73526-002, and Equate Medicated Vaporizing Steam Liquid, NDC 73559-011, as required under section 510(j) of the FD&C Act, 21 U.S.C. 360(j). Failure to provide complete listing information for a drug in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). Furthermore, these drugs are misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below. CGMP Violations We reviewed your February 27, 2026, response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supporting documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP. During our inspection, our investigators observed specific violations including, but not limited to, the following. 1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22). You manufacture an over-the counter (OTC) drug product, a topical psoriasis cream, for the U.S market. Your quality unit (QU) failed to …
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has BioMylz Pvt. Ltd. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for BioMylz Pvt. Ltd. as of 2026-07-21. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-07-13 FDA Warning Letter: BioMylz Pvt. Ltd. Cited for CGMP/Finished Pharmaceuticals/Adulterated/Misbranded. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-biomylz-pvt-ltd-2026-07-13-cgmp
"2026-07-13 FDA Warning Letter: BioMylz Pvt. Ltd. Cited for CGMP/Finished Pharmaceuticals/Adulterated/Misbranded." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-biomylz-pvt-ltd-2026-07-13-cgmp.
Argus HQ Research. "2026-07-13 FDA Warning Letter: BioMylz Pvt. Ltd. Cited for CGMP/Finished Pharmaceuticals/Adulterated/Misbranded." Digital Empire Holdings LLC. Accessed July 22, 2026. https://argushq.ai/fda/warning-letter/fda-wl-biomylz-pvt-ltd-2026-07-13-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_biomylz_pvt_ltd_2026_07_13_cgmp_2026,
title = {2026-07-13 FDA Warning Letter: BioMylz Pvt. Ltd. Cited for CGMP/Finished Pharmaceuticals/Adulterated/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-biomylz-pvt-ltd-2026-07-13-cgmp},
note = {Accessed: July 22, 2026}
}